The significant association of PCSK9 levels with hs-CRP, sP-selectin, sCD40L and platelet reactivity markers suggested that PCSK9 might contribute to the recurrence of adverse cardiovascular events, at least in part, through promoting inflammation and increasing platelet activation in DM patients during the acute stage of MI. The gene discussed is CD40LG; the disease is myocardial infarction.